We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
Read MoreHide Full Article
Epizyme, Inc. witnessed a loss of 48 cents per share in the second quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 56 cents and a penny narrower than the year-ago loss of 49 cents.
Notably, the company’s stock has stock gained 17% so far this year compared with the Zacks classified industry’s gain of 8.9%.
Quarter in Detail
With no approved products in its portfolio as of yet, Epizyme relies heavily on its collaborators for revenues. In this quarter, the company received $10 million representing milestone payment from GlaxoSmithKline (GSK - Free Report) following their initiation of GLP toxicology studies for a first-in-class methyltransferase inhibitor discovered by Epizyme and licensed to GSK. Revenues exceeded the Zacks Consensus Estimate of $4 million.
Research and development (R&D) expenses increased 27% year over year to $27.3 million. The improvement was primarily owing to the expansion of clinical studies of tazemetostat in several indications and initiation of advance phases in other pipeline candidates.
General and administrative (G&A) expenses were $11.2 million in the quarter, up 51.4% from the year-ago quarter. The uptick was backed by a rise in expenses related to commercial-related activities and legal spending to support the company’s growing intellectual property portfolio.
The company had $193 million of cash, cash equivalents and marketable securities as of Jun 30, 2017 and expects that it will be sufficient to fund its planned operations at least till the third quarter of 2018.
Pipeline Update
In July, the company announced positive interim data in the epithelioid sarcoma (ES) cohort from the phase II study in adult patients with INI1-negative solid tumors. It expects to file the first new drug application for tazemetostat to the FDA for epithelioid sarcoma in 2018.
Meanwhile, Epizyme continues to advance its lead candidate, tazemetostat in multiple clinical trials in a range of solid tumors and hematological malignancies, and as both a monotherapy and in combination with other anti-cancer agents. The company has collaborated with Roche Holding AG (RHHBY - Free Report) to evaluate tazemetostat in combination with Tecentriq.
In June 2017, the company had announced that tazemetostat will be evaluated in combination with Tecentriq in a phase Ib/II study of metastatic non-small cell lung cancer as part of Genentech's (a member of the Roche Group) MORPHEUS study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in solid tumors. This study is expected to begin enrolling patients by the end of 2017.
In the same month, positive interim efficacy data, grouped by EZH2 mutational status, were also presented from the ongoing phase II study of tazemetostat as a single-agent treatment for relapsed or refractory patients with follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 64.5% year to date.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
Epizyme, Inc. witnessed a loss of 48 cents per share in the second quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 56 cents and a penny narrower than the year-ago loss of 49 cents.
Notably, the company’s stock has stock gained 17% so far this year compared with the Zacks classified industry’s gain of 8.9%.
Quarter in Detail
With no approved products in its portfolio as of yet, Epizyme relies heavily on its collaborators for revenues. In this quarter, the company received $10 million representing milestone payment from GlaxoSmithKline (GSK - Free Report) following their initiation of GLP toxicology studies for a first-in-class methyltransferase inhibitor discovered by Epizyme and licensed to GSK. Revenues exceeded the Zacks Consensus Estimate of $4 million.
Research and development (R&D) expenses increased 27% year over year to $27.3 million. The improvement was primarily owing to the expansion of clinical studies of tazemetostat in several indications and initiation of advance phases in other pipeline candidates.
General and administrative (G&A) expenses were $11.2 million in the quarter, up 51.4% from the year-ago quarter. The uptick was backed by a rise in expenses related to commercial-related activities and legal spending to support the company’s growing intellectual property portfolio.
The company had $193 million of cash, cash equivalents and marketable securities as of Jun 30, 2017 and expects that it will be sufficient to fund its planned operations at least till the third quarter of 2018.
Pipeline Update
In July, the company announced positive interim data in the epithelioid sarcoma (ES) cohort from the phase II study in adult patients with INI1-negative solid tumors. It expects to file the first new drug application for tazemetostat to the FDA for epithelioid sarcoma in 2018.
Meanwhile, Epizyme continues to advance its lead candidate, tazemetostat in multiple clinical trials in a range of solid tumors and hematological malignancies, and as both a monotherapy and in combination with other anti-cancer agents. The company has collaborated with Roche Holding AG (RHHBY - Free Report) to evaluate tazemetostat in combination with Tecentriq.
In June 2017, the company had announced that tazemetostat will be evaluated in combination with Tecentriq in a phase Ib/II study of metastatic non-small cell lung cancer as part of Genentech's (a member of the Roche Group) MORPHEUS study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in solid tumors. This study is expected to begin enrolling patients by the end of 2017.
In the same month, positive interim efficacy data, grouped by EZH2 mutational status, were also presented from the ongoing phase II study of tazemetostat as a single-agent treatment for relapsed or refractory patients with follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
Epizyme, Inc. Price, Consensus and EPS Surprise
Epizyme, Inc. Price, Consensus and EPS Surprise | Epizyme, Inc. Quote
Zacks Rank & Key Pick
Epizyme currently holds a Zacks Rank #2 (Buy). Another top-ranked stock in the pharma sector is Enzo Biochem, Inc. (ENZ - Free Report) sporting the same rank as the former. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 64.5% year to date.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>